Duane D. Miller, Ph.D.
Van Vleet Professor and Chair
Department of Pharmaceutical Sciences
The University of Tennessee Health Science Center
227c Johnson Building
847 Monroe Avenue
Memphis, TN 38163
Tel: (901) 448-6026
Fax: (901) 448-6828
Email: Duane D. Miller
- Ph.D. Institution: University of Washington, Medicinal Chemistry Department
The design, synthesis and characterization of new drug molecules for mechanism based structure-activity relationships is the primary focus of our laboratory. One of the important areas of research is studying new drugs affecting the central and peripheral nervous systems. Our laboratory is very interested in the design of drugs that are used to treat asthma, emphysema and obesity. Other areas of keen interest are drugs used to treat and diagnose prostate cancer and diabetic complications.
We are currently investigating the modification of a molecule called trimetoquinol which is used in Japan. We are attempting to make chemical structural changes in the molecule so that it can be used to activate selectively beta 2-adrenergic receptors found in lung tissue. We are also attempting to make changes that will also convert this same molecule into a beta 3-adrenergic receptor agonist for the treatment of obesity. The latter receptors are found in adipose tissue and upon activation lead to the breakdown of fat. We are also in the process of studying medetomidine, an alpha-adrenergic agonist. We are changing the structure of medetomidine chemically to see if such changes can lead to a better understanding of how this molecule binds to the various subtypes of a- adrenergic receptors.
We are very interested in drugs that could interfere with the craving for cocaine. We are now synthesizing drugs that will block specific glutamate receptors found in the brain and hopefully such new information will help us find an agent that will be useful in treating cocaine addiction.
Drugs that bind to androgen receptors and their relationship to prostate cancer are being studied in our laboratory. A major project is directed toward synthesizing new radiolabeled androgen ligands and we plan to use this technology towards imaging metastatic prostate cancer.
A major enzyme in the development of diabetic complications such as cataracts is thought to be the enzyme aldose reductase. Our laboratory has developed irreversible inhibitors for studying this enzyme.
- Xiao M, Ahn S, Wang J, Chen J, Miller DD, Dalton JT, Li W. Discovery of 4-Aryl-2-benzoyl-imidazoles as Tubulin Polymerization Inhibitor with Potent Antiproliferative Properties. J Med Chem. 2013 Apr 25;56(8):3318-29. doi: 10.1021/jm4001117. Epub 2013 Apr 9. PubMed PMID: 23547728.
- Bukiya AN, McMillan JE, Fedinec AL, Patil SA, Miller DD, Leffler CW, Parrill AL, Dopico AM. Cerebrovascular Dilation via Selective Targeting of the Cholane Steroid-Recognition Site in the BK Channel ╬▓1-Subunit by a Novel Nonsteroidal Agent. Mol Pharmacol. 2013 May;83(5):1030-44. doi: 10.1124/mol.112.083519. Epub 2013 Mar 1. PubMed PMID: 23455312; PubMed Central PMCID: PMC3629834.
- Patil SA, Patil R, Miller DD. Indole molecules as inhibitors of tubulin polymerization: potential new anticancer agents. Future Med Chem. 2012 Oct;4(16):2085-115. doi: 10.4155/fmc.12.141. Review. PubMed PMID: 23157240.
- Mundra V, Lu Y, Danquah M, Li W, Miller DD, Mahato RI. Formulation and characterization of polyester/polycarbonate nanoparticles for delivery of a novel microtubule destabilizing agent. Pharm Res. 2012 Nov;29(11):3064-74. doi: 10.1007/s11095-012-0881-7. Epub 2012 Sep 28. PubMed PMID: 23054088; PubMed Central PMCID: PMC3646297.
- Kiss GN, Fells JI, Gupte R, Lee SC, Liu J, Nusser N, Lim KG, Ray RM, Lin FT, Parrill AL, S├╝megi B, Miller DD, Tigyi G. Virtual screening for LPA2-specific agonists identifies a nonlipid compound with antiapoptotic actions. Mol Pharmacol. 2012 Dec;82(6):1162-73. doi: 10.1124/mol.112.079699. Epub 2012 Sep 11. PubMed PMID: 22968304; PubMed Central PMCID: PMC3502618.
- Bukiya AN, Patil SA, Li W, Miller DD, Dopico AM. Calcium- and voltage-gated potassium (BK) channel activators in the 5╬▓-cholanic acid-3╬▒-ol analogue series with modifications in the lateral chain. ChemMedChem. 2012 Oct;7(10):1784-92. doi: 10.1002/cmdc.201200290. Epub 2012 Sep 4. PubMed PMID: 22945504.